TRMT61B

Across TCGA pan-cancer cohorts, TRMT61B mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TRMT61B data layer compared with 27 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher TRMT61B mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated TRMT61B expression acts as an unfavorable survival marker, although some lineages such as LSCC and PDAC show a favorable association.

LSCC, PDAC, and HNSC are the cancer types where TRMT61B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Tertile	II,III,IV	0.954	0.593	.001	24	view →
PDAC	DFS	Median	IV	0.785	0.214	.006	9	view →
HNSC	OS	Quartile	All	0.775	0.940	.019	6	view →
GBM	OS	Quartile	All	0.664	0.293	.039	2	view →
LUAD	OS	Median	All	0.803	0.950	.046	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TRMT61B–LSCC (DFS)

Open the LSCC breakdown →